Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer To Acquire Worldwide Rights to Exubera | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pfizer To Acquire Worldwide Rights to Exubera

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer has reached an agreement to acquire the Sanofi-Aventis worldwide rights to inhaled human insulin for $1.3 billion. Pfizer intends to market the drug under the trade name Exubera. The two companies were previously in a worldwide alliance to co-develop, co-promote and co-manufacture Exubera. Also, Pfizer will acquire the insulin production facilities located in Frankfurt, Germany, previously jointly owned by the two companies.

Exubera is a fast-acting dry powder formulation of human insulin and is inhaled into the lungs via the mouth pre-meal through a hand-held inhalation device. Exubera is under regulatory review in the U.S. and Europe for the treatment of adults with both type 1 and type 2 diabetes. Pfizer plans to make Exubera available to patients as soon as possible following regulatory approvals.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters